Communiqués de presse Archive - Page 13 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Communiqués de presse Archive - Page 13 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
    • Newsletter
  • Contact
en
  • fr

P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s

October 2021

OSE Immunotherapeutics Announces H1 2021 Results

October 2021

OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial

October 2021

OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial

October 2021

Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor

October 2021

Boehringer Ingelheim and OSE Immunotherapeutics To Present Phase 1 Results with BI 765063

October 2021

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

October 2021

OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

October 2021

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi®

October 2021

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial

October 2021

OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day

  • Précédent
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 21
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris